|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.75 USD | -1.57% |
|
-1.16% | -13.75% |
| 03-11 | Legend Biotech Shares Likely to Rebound in 2026 on Robust Fundamentals, RBC Says | MT |
| 03-11 | RBC Cuts Price Target on Legend Biotech to $62 From $66, Keeps Outperform Rating | MT |
Company Valuation: Legend Biotech Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 7,175 | 8,357 | 10,938 | 5,969 | 4,015 | 3,468 | - | - |
| Change | - | 16.46% | 30.89% | -45.43% | -32.74% | -13.64% | - | - |
| Enterprise Value (EV) 1 | 6,446 | 7,855 | 9,959 | 4,496 | 4,015 | 2,622 | 2,338 | 1,873 |
| Change | - | 21.86% | 26.78% | -54.85% | -10.7% | -34.71% | -10.83% | -19.88% |
| P/E ratio | -17x | -17.8x | -20.5x | -33.9x | -13.4x | 184x | 16.3x | 10.6x |
| PBR | 15.3x | - | 8.75x | 5.74x | - | 3.23x | 2.55x | 1.9x |
| PEG | - | -8.13x | -4.1x | 0.5x | -0.2x | -2x | 0x | 0.2x |
| Capitalization / Revenue | 79.9x | 71.4x | 38.4x | 9.52x | 3.9x | 2.4x | 1.9x | 1.64x |
| EV / Revenue | 71.8x | 67.1x | 34.9x | 7.17x | 3.9x | 1.82x | 1.28x | 0.88x |
| EV / EBITDA | -17.9x | -17.7x | -25.4x | -39.7x | -37.4x | 21.1x | 6.33x | 3.14x |
| EV / EBIT | -17.3x | -17.2x | -24.1x | -32.9x | -29.4x | 42.1x | 6.81x | 3.41x |
| EV / FCF | -26.6x | -33.1x | -24.1x | -28.4x | - | 19.5x | 5.61x | 2.96x |
| FCF Yield | -3.76% | -3.02% | -4.15% | -3.52% | - | 5.12% | 17.8% | 33.8% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.74 | -2.8 | -2.94 | -0.96 | -1.62 | 0.102 | 1.15 | 1.776 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 89.79 | 117 | 285.1 | 627.2 | 1,029 | 1,442 | 1,822 | 2,119 |
| EBITDA 1 | -360.6 | -443.2 | -392.1 | -113.2 | -107.5 | 124.2 | 369.5 | 596.3 |
| EBIT 1 | -373 | -455.8 | -412.6 | -136.5 | -136.5 | 62.21 | 343.2 | 549.9 |
| Net income 1 | -386.2 | -446.3 | -518.3 | -177 | -296.8 | 67.06 | 308.4 | 499.2 |
| Net Debt 1 | -729.5 | -501.5 | -979.4 | -1,473 | - | -846 | -1,130 | -1,595 |
| Reference price 2 | 46.61 | 49.92 | 60.17 | 32.54 | 21.74 | 18.75 | 18.75 | 18.75 |
| Nbr of stocks (in thousands) | 153,946 | 167,403 | 181,789 | 183,451 | 184,690 | 184,943 | - | - |
| Announcement Date | 18/03/22 | 30/03/23 | 11/03/24 | 11/03/25 | 10/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 183.82x | 1.82x | 21.1x | -.--% | 3.47B | |
| 41.47x | 9.67x | 34.91x | 0.03% | 42.98B | |
| 15.59x | 5.54x | 12.2x | 1.92% | 39.24B | |
| -51.87x | 17.46x | -57.69x | -.--% | 30.07B | |
| -17.46x | 4.3x | -8.04x | -.--% | 21.88B | |
| 27.73x | 5.41x | 15.05x | -.--% | 18.25B | |
| 21.68x | 4.07x | 13.29x | -.--% | 16.03B | |
| -316.87x | 26.28x | 1446.95x | -.--% | 12.97B | |
| -14.42x | 6446.99x | -18.43x | -.--% | 12.5B | |
| -164.89x | 40.26x | -159.9x | -.--% | 11.76B | |
| Average | -27.52x | 656.18x | 129.94x | 0.19% | 20.91B | |
| Weighted average by Cap. | -20.49x | 396.00x | 82.64x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- LEGN Stock
- Valuation Legend Biotech Corporation
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition